Less Ads, More Data, More Tools Register for FREE

Pin to quick picksIxico Regulatory News (IXI)

Share Price Information for Ixico (IXI)

Share Price is delayed by 15 minutes
Get Live Data
8.65    0.00 (0.00%)
Bid:
8.30
Ask:
9.00
Spread: 0.70 (8.434%)
Market Cap: £18.86m
IXI Live PriceLast checked at - London Stock Exchange

Intraday Ixico Share Chart

Director/PDMR Shareholding

15 Jan 2020 10:32

RNS Number : 8891Z
IXICO plc
15 January 2020
 

15 January 2020

 

IXICO plc

("IXICO" or the "Company")

 

Exercise of Options and PDMR Dealings

IXICO plc (AIM: IXI), the data analytics company delivering insights in neuroscience, announces that it received notification on 10 January 2020 that John Hall, SVP Corporate Development and PDMR, exercised 75,000 options with an exercise price of 34p.

 

The Company has also received notification on 10 January 2020 that Robin Wolz, SVP Research & Development and PDMR, exercised 83,882 options of which 45,176 were exercisable at 30.5p and 38,706 were exercisable at 34p. The 83,882 shares were sold to a third party at an average price of 87.6p.

 

 

1

 

Details of the person discharging managerial responsibilities / person closely associated

 

a)

 

Name

 

 

John James Hall

 

2

 

Reason for the notification

 

a)

 

Position/status

 

 

PDMR (SVP Corporate Development)

b)

 

Initial notification /Amendment

 

 

Initial notification

3

 

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

 

a)

 

Name

 

 

IXICO plc

b)

 

LEI

 

 

2138005M1F59O6HWSA97

4

 

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

 

 

a)

 

Description of the financial instrument, type of instrument

Ordinary Shares in IXICO plc

Identification code

GB00BCLY7L40

 

b)

 

Nature of the transaction

 

 

Exercise of options

c)

 

Price(s) and volume(s)

 

 

 

 

 

Exercise Price(s)

Volume(s)

 

 

34p

75,000

 

 

 

 

 

d)

 

Aggregated information

- Aggregated volume

75,000 shares

- Price

34p

e)

 

Date of the transaction

 

 

10/1/20

f)

 

Place of the transaction

 

 

N/A

 

1

 

Details of the person discharging managerial responsibilities / person closely associated

 

a)

 

Name

 

 

Robin Wolz

 

2

 

Reason for the notification

 

a)

 

Position/status

 

 

PDMR (SVP Research & Development)

b)

 

Initial notification /Amendment

 

 

Initial notification

3

 

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

 

a)

 

Name

 

 

IXICO plc

b)

 

LEI

 

 

2138005M1F59O6HWSA97

4

 

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

 

 

a)

 

Description of the financial instrument, type of instrument

Ordinary Shares in IXICO plc

Identification code

GB00BCLY7L40

 

b)

 

Nature of the transaction

 

 

Exercise of options

c)

 

Price(s) and volume(s)

 

 

 

 

 

Exercise Price(s)

Volume(s)

 

 

30.5p

45,176

 

 

34p

38,706

 

 

 

 

 

d)

 

Aggregated information

- Aggregated volume

83,882 shares

- Price

32.1p

e)

 

Date of the transaction

 

 

10/1/20

f)

 

Place of the transaction

 

 

N/A

 

1

 

Details of the person discharging managerial responsibilities / person closely associated

 

 

a)

 

Name

 

 

Robin Wolz

 

 

2

 

Reason for the notification

 

 

a)

 

Position/status

 

 

PDMR (SVP Research & Development)

 

b)

 

Initial notification /Amendment

 

 

Initial notification

 

3

 

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

 

 

a)

 

Name

 

 

IXICO plc

 

b)

 

LEI

 

 

2138005M1F59O6HWSA97

 

4

 

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

 

 

 

a)

 

Description of the financial instrument, type of instrument

Ordinary Shares in IXICO plc

 

 

Identification code

GB00BCLY7L40

 

 

 

b)

 

Nature of the transaction

 

 

Sale

 

c)

 

Price(s) and volume(s)

 

 

 

 

 

 

Price(s) Date

Volume(s)

 

 

 

92p 10/1/20

18,395

 

 

 

90p 13/1/20

18,395

 

 

 

85p 13/1/20

47,092

 

 

 

 

 

 

 

d)

 

Aggregated information

 

 

- Aggregated volume

83,882 shares

 

 

- Price

87.6p

 

 

e)

 

Date of the transaction

 

 

10/1/20 and 13/1/20

 

f)

 

Place of the transaction

 

 

London Stock Exchange

 

 

IXICO plc

+44 (0) 20 3763 7498

Giulio Cerroni, Chief Executive Officer

Grant Nash, Chief Financial Officer

 

Cenkos Securities PLC (Nominated adviser and sole broker)

+44 (0) 20 7397 8900

Giles Balleny / Max Gould (Corporate Finance)

Michael F Johnson / Russell Kerr (Sales)

Optimum Strategic Communications

 +44 (0) 203 950 9144

Mary Clark / Supriya Mathur/Manel Mateus

ixico@optimumcomms.com

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
DSHBELFFBFLXBBB
Date   Source Headline
8th Jun 20267:00 amRNSScientific advisors & partners update
22nd May 20267:00 amRNS-RCompany presentation at Mello 2026
21st May 20267:00 amRNSContract win and contract extension
19th May 20267:00 amRNSInterim results for six months ending 31/03/2026
12th May 20267:00 amRNSIXICO Updates AI Neuroimaging Platform
28th Apr 20262:31 pmRNSHolding(s) in Company
28th Apr 20261:50 pmRNSHolding(s) in Company
28th Apr 202611:45 amRNSHolding(s) in Company
28th Apr 202610:49 amRNSHolding(s) in Company
27th Apr 20264:02 pmRNSHolding(s) in Company
27th Apr 20263:57 pmRNSHolding(s) in Company
27th Apr 20263:55 pmRNSHolding(s) in Company
27th Apr 20261:51 pmRNSHolding(s) in Company
27th Apr 202611:13 amRNSHolding(s) in Company
24th Apr 20263:30 pmRNSHolding(s) in Company
22nd Apr 202612:40 pmRNSIssue of Equity
21st Apr 20267:00 amRNSTrading Update
16th Apr 202612:01 pmRNSResult of GM and Update on Issue of Equity
7th Apr 20261:14 pmRNSResult of Retail Offer
31st Mar 20267:01 amRNSRetail Offer
31st Mar 20267:00 amRNSPlacings and Subscription
26th Mar 20267:00 amRNSCollaboration with Medidata
26th Feb 20267:00 amRNSValidation of Neuroimaging Technology Platform
12th Feb 20268:48 amRNSCorrection: c.£1.5 million Contract Extension
12th Feb 20267:00 amRNSc.£1.5 million Contract Extension
5th Feb 20267:00 amRNSAppointment of Chief Commercial Officer
23rd Jan 20265:05 pmRNSResults of AGM
9th Dec 20257:05 amRNSShare option award
9th Dec 20257:00 amRNSFinancial Results for year ended 30 September 2025
1st Dec 20257:00 amRNSOperational Update
27th Nov 20257:00 amRNSNotice of 2025 Full Year Results and IMC
17th Nov 20257:00 amRNSClinical Trial Contract Win
3rd Nov 20252:30 pmRNSCapital Markets Day Presentation and Video
16th Oct 20257:00 amRNSTrading Update
15th Oct 20257:00 amRNSNew contract win and contract extension
30th Sep 20257:00 amRNSNotice of Capital Markets Day
12th Aug 20257:00 amRNSContract Win
22nd Jul 20257:00 amRNSStrategic Data Partnership with GAP
17th Jul 20257:00 amRNSTrading Update
13th Jun 20258:03 amRNSShare option awards and PDMR Dealing
10th Jun 20257:00 amRNSFDA Clearance of Alzheimer's Diagnostic Biomarker
20th May 20256:00 pmRNSHolding(s) in Company
20th May 20257:00 amRNSHalf-year Report
8th May 202511:30 amRNSHolding(s) in Company
6th May 20257:00 amRNSNotice of Interim Results & Investor Presentation
16th Apr 20257:00 amRNSTrading Update
27th Feb 20257:00 amRNSContract Win
12th Feb 20257:00 amRNSFurther Validation of IXICO’s AI Imaging Platform
7th Feb 20253:00 pmRNSIssue of share options and PDMR dealing
24th Jan 20252:16 pmRNSResult of AGM

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.